NC
VTGN icon

Nexthera Capital’s VistaGen Therapeutics VTGN Stock Holding History

Nexthera Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,604
Closed -$154K – 53
2017
Q4 		$154K Hold
4,604
– – 0.03% 39
2017
Q3 		$221K Hold
4,604
– – 0.06% 36
2017
Q2 		$258K Hold
4,604
– – 0.11% 41
2017
Q1 		$271K Hold
4,604
– – 0.14% 34
2016
Q4 		$515K Hold
4,604
– – 0.3% 35
2016
Q3 		$575K Hold
4,604
– – 0.35% 30
2016
Q2 		$539K Buy
+4,604
New +$528K 0.47% 28

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $192M AUM 20.53% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nexthera Capital's VTGN Position: Q1 2018 in Review

Nexthera Capital sold out of VistaGen Therapeutics (VTGN) in Q1 2018, closing a stake of 4,604 shares — an estimated $154K sold.

Nexthera Capital first reported a position in VTGN in Q2 2016 and held it in 7 quarters. The position peaked at $575K in Q3 2016. 20 funds tracked by Wall St. Rank hold VTGN as of Q1 2018.

  • Nexthera Capital reported no remaining VistaGen Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Nexthera Capital sold 4,604 VistaGen Therapeutics shares in Q1 2018, an estimated $154K.
  • Nexthera Capital first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 7 quarters.
  • Nexthera Capital's VistaGen Therapeutics position peaked at $575K in Q3 2016.
  • 20 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2018.

Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.